O'Hagan Shaun, Galway Niamh, Shields Michael D, Mallett Peter, Groves Helen E
Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland.
Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland.
Drug Healthc Patient Saf. 2023 Sep 11;15:103-112. doi: 10.2147/DHPS.S348727. eCollection 2023.
Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific "high-risk" populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.
呼吸道合胞病毒（RSV）是全球范围内导致儿童发病和死亡的主要原因。帕利珠单抗是一种可提供针对RSV的被动免疫的单克隆抗体，目前已获许可用于特定“高危”人群的预防，包括先天性心脏病、支气管肺发育不良和早产。现有研究表明，在这些高危人群中使用帕利珠单抗可降低与RSV相关的住院率。然而，尚未证实帕利珠单抗能降低与RSV相关的死亡率、不良事件或住院时间。在本文中，我们回顾了RSV的管理、帕利珠单抗预防的适应症、这种预防性药物的安全性、成本效益和疗效，以及可能彻底改变未来对这种重要病原体预防的新兴疗法。
